Man Wu, Pok Man Hau, Linxian Li, Chi Man Tsang, Yike Yang, Aziz Taghbalout, Grace Tin-Yun Chung, Shin Yee Hui, Wing Chung Tang, Nathaniel Jillette, Jacqueline Jufen Zhu, Horace Hok Yeung Lee, Ee Ling Kong, Melissa Sue Ann Chan, Jason Ying Kuen Chan, Brigette Buig Yue Ma, Mei-Ru Chen, Charles Lee, Ka Fai To, Albert Wu Cheng, Kwok-Wai Lo
The unique virus-cell interaction in Epstein-Barr virus (EBV)-associated malignancies implies targeting the viral latent-lytic switch is a promising therapeutic strategy. However, the lack of specific and efficient therapeutic agents to induce lytic cycle in these cancers is a major challenge facing clinical implementation. We develop a synthetic transcriptional activator that specifically activates endogenous BZLF1 and efficiently induces lytic reactivation in EBV-positive cancer cells. A lipid nanoparticle encapsulating nucleoside-modified mRNA which encodes a BZLF1-specific transcriptional activator (mTZ3-LNP) is synthesized for EBV-targeted therapy...
May 3, 2024: Nature Communications